|
CR Intrinsic Agrees to Pay More than $600 Million in Largest-Ever Settlement for Insider Trading CaseInfographicFOR IMMEDIATE RELEASE2013-41
Washington,
D.C., March 15, 2013
— The Securities and Exchange Commission today announced that
Stamford, Conn.-based hedge fund advisory firm CR Intrinsic
Investors has agreed to pay more than $600 million to settle SEC
charges that it participated in an insider trading scheme
involving a clinical trial for an Alzheimer’s drug being jointly
developed by two pharmaceutical companies.
The
SEC
charged CR Intrinsic with insider trading
in November 2012, alleging that one of the firm’s portfolio
managers Mathew Martoma illegally obtained confidential details
about the clinical trial from Dr. Sidney Gilman, who was selected
by the pharmaceutical companies — Elan Corporation and Wyeth —
to present the final drug trial results to the public.
|
The
settlement filed today in federal court in Manhattan is the largest
ever in an insider trading case, requiring CR Intrinsic — an
affiliate of S.A.C. Capital Advisors — to pay $274,972,541 in
disgorgement, $51,802,381.22 in prejudgment interest, and a
$274,972,541 penalty.
No comments:
Post a Comment